Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Sandoz Set For 2026 Generic Semaglutide Launch in Canada

Sep 3, 2024

On 3 September 2024, Bloomberg reported that Sandoz is planning a 2026 biosimilar semaglutide launch in Canada, reportedly after Novo Nordisk’s patent protection expires.  Sandoz launches in the US and Europe are not planned until the early 2030s.

This comes after Biocon’s announcement in April 2024 that it entered an exclusive licensing and supply agreement with Biomm for generic Ozempic® (semaglutide) in Brazil.  In the same month, Hangzhou Jiuyan Gene Engineering’s application for generic Ozempic® was accepted by regulators in China.